AU Patent

AU2014200364B2 — Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1A activity

Assigned to H Lundbeck AS · Expires 2015-09-17 · 11y expired

What this patent protects

THERAPEUTIC USES OF COMPOUNDS HAVING COMBINED SERT, 5 HT3 AND 5-HT1A ACTIVITY New pharmaceutical uses of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine and pharmaceutically acceptable salts thereof are provided.

USPTO Abstract

THERAPEUTIC USES OF COMPOUNDS HAVING COMBINED SERT, 5 HT3 AND 5-HT1A ACTIVITY New pharmaceutical uses of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine and pharmaceutically acceptable salts thereof are provided.

Drugs covered by this patent

vortioxetine-hydrobromide (VORTIOXETINE HYDROBROMIDE)

Patent Metadata

Patent number: AU2014200364B2
Jurisdiction: AU
Classification: —
Expires: 2015-09-17
Drug substance claim: No
Drug product claim: No
Assignee: H Lundbeck AS
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.